We showed here that GH drives several therapy-resistance mechanisms in PDAC, focusing mainly on the GH-induced increase in ABC transporter expression and induction of the EMT pathway, which are only part of the molecular mechanisms underlying gemcitabine resistance in cancer. This evidence concerns the gene ABCG2 and cancer.